Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 6%
Buy 25%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care has demonstrated strong revenue growth potential, with projected revenues increasing from $1.109 million in 2026 to $1.111 million, and further to $1.229 million in 2027. The company anticipates re-establishing positive new patient start growth in the US at approximately 4% year-over-year, fueled by conversion from multiple daily injections and enhanced access through pharmacy channels. Additionally, Tandem's recent revenue performance exceeded expectations by about $14 million, primarily due to a strong presence in the US market and increased pricing power from pharmacy channel penetration.

Bears say

Tandem Diabetes Care has faced significant operating losses since its inception and fails to guarantee sustained profitability, which raises concerns about its financial stability. The company anticipates flat to slightly declining new patient starts in the U.S. for 2025, with estimated pump shipments reflecting a 4% year-over-year decrease, indicating potential challenges in market demand. Additionally, risks such as competitive pressures, contract negotiations in the pharmacy channel, and inadequate growth from new product launches like the Mobi pump could negatively impact Tandem's future revenue and profitability prospects.

TNDM has been analyzed by 16 analysts, with a consensus rating of Hold. 6% of analysts recommend a Strong Buy, 25% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Hold based on their latest research and market trends.

According to 16 analysts, TNDM has a Hold consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.